Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.
Patients with non-small cell lung cancer who tested positive for driver gene alteration had longer overall survival when given targeted therapy.
Sandip P. Patel, MD, discusses the utilization of sacituzumab govitecan in non–small cell lung cancer, highlighting trials in which the TROP2-directed antibody-drug conjugate is being evaluated in this patient population.
Dr. Eduardo Santos, MD, FACP, FCCP, highlights advancements in neoadjuvant immunotherapy for NSCLC presented during key conferences in 2023, underscoring pivotal findings and the potential transformation of treatment approaches.
Dr. Eduardo Santos, MD, FACP, FCCP, provides and overview of immunotherapy-based treatment strategies for NSCLC in the neoadjuvant and perioperative setting.